An experimental drug developed by Roche has failed to meet its primary endpoints in a late-stage trial.
The drug, etrolizumab, was developed to treat patients with moderate to severe ulcerative colitis. Roche announced on Monday that studies evaluating etrolizumab as an induction therapy were mixed, and that the drug also failed as a maintenance therapy compared to a placebo.
Roche’s chief medical officer called the results “disappointing” and said that “people with ulcerative colitis “need treatments now.”
The drug is still being evaluated as a treatment for Crohn’s disease.
Read the full Reuters report.
